COMMUNIQUÉS West-GlobeNewswire

Mereo BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
12/05/2026
LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced financial results for [...]
Vireo Growth Inc. Announces First Quarter 2026 Results
12/05/2026
Q1 GAAP revenue of $106.2 million increased 333.5% year-over-year, driven by recently closed M&A transactions Moves to 4 th largest cannabis company on a pro forma basis by revenue Closed the Schwazze acquisition [...]
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
12/05/2026
On track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 for XTX501, a potential best-in-class bispecific PD-1 / masked IL-2 Presented new preclinical data for XTX601, a [...]
BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients
12/05/2026
Over 315 patients screened and over 230 patients enrolled in BriaCell’s pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor in metastatic breast cancer Enrollment momentum continues with strong [...]
Harvard Bioscience Announces First Quarter 2026 Financial Results
12/05/2026
First Quarter 2026 Revenues of $20.8M and Gross Margin of 59% Consolidation of Manufacturing Operations Progressing on Schedule Reaffirms Full Year 2026 Financial Guidance HOLLISTON, Mass., May 12, 2026 (GLOBE NEWSWIRE [...]
Aveanna to Participate at the William Blair 46th Annual Growth Stock Conference
12/05/2026
ATLANTA, May 12, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the William Blair 46 th Annual Growth Stock Conference in [...]
Compass Therapeutics to Participate in Upcoming May Investor Events
12/05/2026
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human [...]
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
12/05/2026
Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027 Reported additional Phase 1 data for SAB-142 [...]
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
12/05/2026
– First-ever FDA approved PROTAC supports the further development and potential of Arvinas’ pipeline – – Announced FDA Approval of VEPPANU ™ (vepdegestrant) for the treatment of ESR1m, ER+/HER2- advanced breast cancer [...]
Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona Pharma
12/05/2026
Christopher Martin joins the Board of Directors, with Mark Zappia and Jim Willis joining as Senior Vice President of Commercial and Vice President of Sales, reuniting the team behind the launch of Ohtuvayre®, one of the [...]
NeurAxis Reports Record First Quarter 2026 Financial Results Driven by 80% Year Over Year Revenue Growth
12/05/2026
Conference call will be held today, Tuesday, May 12 at 9:00 am ET CARMEL, Ind., May 12, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company [...]
CorVel Corporation to Host Live Earnings Release Webcast
12/05/2026
FORT WORTH, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL), a leading provider of innovative risk management solutions, is pleased to announce that it will host a live webcast to discuss its [...]
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
12/05/2026
Initiated enrollment of Phase 1 Study of PRT12396, mutant-selective JAK2V617F inhibitor in patients with polycythemia vera (PV) and myelofibrosis (MF) The Company expects to file the IND for PRT13722, first-in-class [...]
Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
12/05/2026
FREDERICK, Md., May 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced [...]
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
12/05/2026
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM Co-founder and CEO, Dr Andrea Pfeifer, to retire after a distinguished 23-year tenure Board Chair, Martin Zügel, MD, to be appointed interim CEO Dr [...]
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May
12/05/2026
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting [...]
Immatics Announces First Quarter 2026 Financial Results and Business Update
12/05/2026
SUPRAME Phase 3 interim and final analysis for PRAME cell therapy, anzu-cel, expected to be triggered in 2026, advancing toward the Company’s first commercial launch planned in 2027 Multiple key clinical data sets [...]
Arbor Biotechnologies Achieves Unprecedented Precise In Vivo Reverse Transcriptase Editing in the Brain Using a Single AAV Vector, Opening a New Path to Treatments for Neurological Diseases
12/05/2026
- Oral presentation at ASGCT showcases breakthrough technology enabling precise in vivo genome editing in the CNS using a single AAV vector - Two poster presentations describe methods that support accelerated [...]
Infex Therapeutics secures £4.3 million funding to advance anti-infective pipeline targeting drug-resistant infections
12/05/2026
Investment led by Jon Moulton supports progression of clinical and preclinical programmes addressing critical-priority pathogens Infex to present results from Phase IIa trial for first-in-class anti-virulence therapy [...]

Pages